Kairos Pharma Reports No Revenue and $5.45 Million Net Loss in Annual Filing

**Kairos Pharma, LTD. Reports Financial Results and Strategic Developments in Annual Filing**

Kairos Pharma, LTD., a clinical-stage biopharmaceutical company, released its annual report on Form 10-K, outlining its financial performance and strategic initiatives. The company, focused on developing therapeutics for cancer patients, reported no revenue for the fiscal year, consistent with its status as a development-stage entity. Operating expenses totaled $5.57 million, comprised of $2.14 million in research and development and $3.44 million in general and administrative costs. This resulted in a loss from operations of $5.57 million.

Compared to the previous fiscal year, research and development expenses increased significantly, driven primarily by ongoing Phase 2 trial in prostate cancer. General and administrative expenses also rose, mainly due to costs associated with being a publicly traded company, including increased insurance premiums and professional service fees. The company reported other income of $0.13 million, primarily from interest income, a shift from the previous year's other expenses of $0.26 million, which included interest expense, financing costs, and debt discount amortization. The net loss for the year was $5.45 million, or $0.30 per share, compared to a net loss of $2.60 million, or $0.23 per share, in the prior year.

Key operational developments included the advancement of its pipeline of seven drugs, with three clinical trials initiated in the fall of 2023 for KROS 201 and ENV 105. The company highlighted the ongoing Phase 2 trial for ENV 105 in prostate cancer, noting a clinical benefit rate of 62% observed in an investigator-initiated trial. Additionally, the NIH awarded a $3.2 million grant to Cedars-Sinai to support the development of the mechanism of action and companion biomarkers for ENV 105. The company also completed pre-IND studies for KROS 101, a small molecule checkpoint inhibitor.

As of December 31, 2025, Kairos Pharma had cash and cash equivalents of $4.49 million. The company has been actively engaged in financing activities, including an equity line of credit agreement with Helena Global Investment Opportunities I LTD, and a private placement offering. The company also entered into an at-the-market offering agreement with H.C. Wainwright Co., LLC for the sale of up to $4.52 million shares of its common stock. The company is relying on single-sourced third parties to conduct the preclinical and nonclinical studies, clinical trials, and manufacture of its clinical trial material for its current in-development products and its future product candidates. The company is also relying exclusively on the skills and expertise of its management team in conducting its business, not all of whom will devote all of their time to managing the Company, and the company currently only has one full-time employee, which may impede its ability to carry on its business.